“AKINETON” RETUNRS TO THE RUSSIAN MARKET AT A REDUCED PRICE
The Antimonopoly Service approved the maximum ex-works prices for the medicine
The story with “Akineton” (bipereden) disappearing from the Russian market, that caused a stir, has reached its logical end. “Desma GmbH” finally met the norms of the law1 and reregistered the medicine price, reduced to the minimum price level in the reference countries. Now the manufacturer’s price for Russian patients on “Akineton” solution 5 mg/ml, 1 ml, 5 ampoules, no more than 167.98 RUB (against earlier registered 611.83 RUB), and for “Akineton” tablets 2 mg, 20 pieces, blister 5 pieces – 223.46 RUB (used to be 423.41 RUB).
Earlier FAS abolished the decisions of the Federal Tariff Services made in 2010 on approving the maximum ex-works prices for the medicine manufactured by “Desma GmbH” (Germany) because at the time of registration the company gave incorrect data: there was no information about medicine prices in the reference countries. The ex-works prices in those countries were considerably low the prices applied for registration in the Russian Federation. It means that prices registered in Russia were unreasonably high.
FAS requested “Desma GmbH” to reduce prices. Instead of reducing many-fold overrated prices and ensuring uninterrupted access of patients to the medicine, the company preferred judicial proceedings. Courts of four instances, including the Supreme Court of the Russian Federation, confirmed legitimacy and reasonableness of FAS actions.
Deputy Head of FAS Andrey Tsarikovskiy said: “The situation with “Akineton” clearly shows that the recent hysteria blown out of proportion by market participants in mass media up around reregistering medicine prices was groundless. For example, the company agreed to reduce prices to the allowed level confirms not only the manufacturer’s interest in the Russian market but also the fact that there is room for companies to reduce prices. Once again, I’d like to repeat that our patients must be able to get medicine at the prices not more expensive than medicine prices in European countries”.
1 No. 865 Decree of the Government of the Russian Federation (version of 08.10.2018) "On state regulation of prices for the medicine included in the list of vital and essential ones” of 29.10.2010